How can drug-drug interactions between small-molecule inhibitors and direct oral anticoagulants be prevented in patients with nonsmall cell lung cancer?
Drug-drug interactions between small-molecule inhibitors and DOACs in nonsmall cell lung cancer patients can be managed by dosage adjustment, administration separation, or switching anticoagulants.
Combinations of SMIs and DOACs often result in relevant DDIs that can be prevented by adjusting the DOAC dosage, separation of administration or switching between anticoagulants.
Otten et al. (Tue,) studied this question.